Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \[¹⁸F\]FAPI-74 PET/CT.
Sponsor: SOFIE
You may qualify if…
- ✓ Male and female adults ≥ 18 years.
- ✓ Participants with confirmed gastric, esophageal or gastroesophageal malignancy undergoing staging evaluation for treatment planning.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
- ✓ Provided signed, written informed consent prior to any study-related procedures.
- ✓ Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \[¹⁸F\]FAPI-74 administration.
- ✓ For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, during the trial intervention period.
You may not qualify if…
- ✕ Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.
- ✕ Known hypersensitivity to \[¹⁸F\]FAPI-74.
- ✕ Administration of another investigational diagnostic or therapeutic product within 30 days prior to \[¹⁸F\]FAPI-74 administration.
- ✕ Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \[¹⁸F\]FAPI-74 administration.
- ✕ Previous cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix/uterus (participants treated with curative intent and disease free for more than 5 years are permitted).
- ✕ Hepatic function: T. bili \>1.5X ULN or alk phos, ALT, or AST \>5X ULN
- ✕ Renal function: GFR \< 30 mL/min
- ✕ Pregnant or currently breast feeding (a negative pregnancy test is required in women of childbearing potential).
Where it's recruiting
Cerritos · Duarte · Irvine · Los Angeles …
Tampa
Indianapolis
Boston · Worcester
Rochester
New York
Cleveland · Kettering
Philadelphia
Source: ClinicalTrials.gov · NCT07217704 · last updated 2026-06-30